Gemcitabine News
Pharmion Corporation Initiates Phase One/Two Combination Clinical Trial With MGCD0103 and Gemzar(R) in Patients With Pancreatic Cancer
Pharmion Corporation, along with its partner MethylGene, Inc., today announced the initiation of a Phase One/Two clinical trial (Trial 006) evaluating its class I-specific histone deacetylase (HDAC) inhibitor product candidate,...
Addition of Gemzar® to Adjuvant Therapy Improves Survival in Early Pancreatic Cancer
According to results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO), the addition of the chemotherapy agent Gemzar® (gemcitabine) to 5-fluorouracil (5-FU) and radiation therapy...
Split Doses of Paraplatin® Decrease Severe Thrombocytopenia in Non–Small Cell Lung Cancer
According to an article recently published in Clinical Lung Cancer, two administrations of lower-dose Paraplatin® (carboplatin) maintains long-term outcomes while decreasing severely low levels of platelets in the treatment of...
Enzon Pharmaceuticals Announces Advancements in Its Oncology Pipeline; Oncaspar Phase I solid tumor trial begins
Today announced the initiation of a phase I clinical trial of Oncaspar to assess its safety and potential utility in the treatment of advanced solid tumors and lymphomas in combination with Gemzar(R) (gemcitabine HCl for...
In The Interests Of Patients, Roche Will Consider All Options Following CHMP Opinion On Tarceva In Pancreatic Cancer
Roche announced today that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for...